Redefining lupus nephritis: Clinical implications of pathophysiologic subtypes

Nature Reviews Nephrology

Volumn 13, Issue 8, 2017, Pages 483-495

  Yu, Feng ^a,b   Haas, Mark ^c   Glassock, Richard ^d   Zhao, Ming Hui ^a,e  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNIVERSITY INTERNATIONAL HOSPITAL   (China)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Tsinghua University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; OCRELIZUMAB; RITUXIMAB;

B LYMPHOCYTE; CELL DAMAGE; CELL THERAPY; CLINICAL ASSESSMENT; DISEASE CLASSIFICATION; GLOMERULONEPHRITIS; HEALTH CARE MANAGEMENT; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; META ANALYSIS (TOPIC); NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PODOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RENOVASCULAR DISEASE; REVIEW; SYSTEMATIC REVIEW (TOPIC); T LYMPHOCYTE; ALGORITHM; ANIMAL; CLASSIFICATION; LUPUS NEPHRITIS; PATHOLOGY;

ALGORITHMS; ANIMALS; HUMANS; LUPUS NEPHRITIS; PODOCYTES;

EID: 85025121734     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2017.85     Document Type: Review

References (145)

1. Bertsias, G. K. et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann. Rheum. Dis. 71, 1771-1782 (2012).
2. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int. Suppl. 2, 139-274 (2012).
3. Hahn, B. H. et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. (Hoboken) 64, 797-808 (2012).
4. Weening, J. J. et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 65, 521-530 (2004).
5. Anders, H. J. & Rovin, B. A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney Int. 90, 493-501 (2016).
6. Gatto, M. et al. Success and failure of biological treatment in systemic lupus erythematosus: a critical analysis. J. Autoimmun. 74, 94-105 (2016).
7. Narain, S. & Furie, R. Update on clinical trials in systemic lupus erythematosus. Curr. Opin. Rheumatol. 28, 477-487 (2016).
8. Parikh, S. V. & Rovin, B. H. Current and emerging therapies for lupus nephritis. J. Am. Soc. Nephrol. 27, 2929-2939 (2016).
9. Zhang, L. et al. Long-term outcomes of end-stage kidney disease for patients with lupus nephritis. Kidney Int. 89, 1337-1345 (2016).
10. Appel, G. B. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20, 1103-1112 (2009).
11. Zavada, J. et al. Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide oron cyclosporine A. Lupus 23, 69-74 (2014).
12. Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64, 1215-1226 (2012).
13. Wofsy, D., Hillson, J. L. & Diamond, B. Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum. 65, 1586-1591 (2013).
14. Banchereau, R. et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165, 551-565 (2016).
15. Haas, M., Rastaldi, M. P. & Fervenza, F. C. Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification. Kidney Int. 85, 779-793 (2014).
16. Wilhelmus, S. et al. The revisited classification of GN in SLE at 10 years: time to re-evaluate histopathologic lesions. J. Am. Soc. Nephrol. 26, 2938-2946 (2015).
17. Parikh, S. V., Alvarado, A., Malvar, A. & Rovin, B. H. The kidney biopsy in lupus nephritis: past, present, and future. Semin. Nephrol. 35, 465-477 (2015).
18. Parikh, S. V., Ayoub, I. & Rovin, B. H. The kidney biopsy in lupus nephritis: time to move beyond histology. Nephrol. Dial. Transplant. 30, 3-6 (2015).
19. Malvar, A. et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol. Dial. Transplant. http:dx.doi.org/10.1093/ndt/gfv296 (2015).
20. Rovin, B. H., Parikh, S. V. & Alvarado, A. The kidney biopsy in lupus nephritis: is it still relevant? Rheum. Dis. Clin. North Am. 40, 537-552 (2014).
21. Zhu, D., Qu, Z., Tan, Y., Yu, F. & Zhao, M. H. Acute kidney injury in Chinese patients with lupus nephritis: a large cohort study from a single center. Lupus 20, 1557-1565 (2011).
22. Churg, J., Bernstein, J. & Classock, R. J. Renal Disease: Classification and Atlas of Glomerular Disease 2nd edn (Igaku-Shoin, 1995).
23. Furness, P. N. & Taub, N. Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis-a UK-wide study. Am. J. Surg. Pathol. 30, 1030-1035 (2006).
24. Grootscholten, C. et al. Interobserver agreement of scoring of histopathological characteristics and classification of lupus nephritis. Nephrol. Dial. Transplant. 23, 223-230 (2008).
25. Yokoyama, H. et al. The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int. 66, 2382-2388 (2004).
26. Chan, T. M. Histological reclassification of lupus nephritis. Curr. Opin. Nephrol. Hypertens. 14, 561-566 (2005).
27. Kojo, S. et al. Clinical usefulness of a prognostic score in histological analysis of renal biopsy in patients with lupus nephritis. J. Rheumatol. 36, 2218-2223 (2009).
28. Markowitz, G. S. & D'Agati, V. D. The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int. 71, 491-495 (2007).
29. Markowitz, G. S. & D'Agati, V. D. Classification of lupus nephritis. Curr. Opin. Nephrol. Hypertens. 18, 220-225 (2009).
30. Schwartz, M. M. The pathology of lupus nephritis. Semin. Nephrol. 27, 22-34 (2007).
31. Schwartz, M. M., Korbet, S. M., Katz, R. S. & Lewis, E. J. Evidence of concurrent immunopathological mechanisms determining the pathology of severe lupus nephritis. Lupus 18, 149-158 (2009).
32. Wilhelmus, S. et al. Interobserver agreement on histopathological lesions in class III or IV lupus nephritis. Clin. J. Am. Soc. Nephrol. 10, 47-53 (2015).
33. Coppo, R. et al. VALIGA study of the ERA-EDTA Immunonephrology Working Group. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 86, 828-836 (2014).
34. Lv, J. et al. Evaluation of the Oxford classification of IgA nephropathy: a systematic review and meta-analysis. Am. J. Kidney Dis. 62, 891-899 (2013).
35. Zeng, C. H. et al. A multicenter application and evaluation of the Oxford classification of IgA nephropathy in adult chinese patients. Am. J. Kidney Dis. 60, 812-820 (2012).
36. Shima, Y. et al. Validity of the Oxford classification of IgA nephropathy in children. Pediatr. Nephrol. 27, 783-792 (2012).
37. Shi, S. F. et al. Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the Oxford classification. Clin. J. Am. Soc. Nephrol. 6, 2175-2184 (2011).
38. Kang, S. H. et al. The Oxford classification as a predictor of prognosis in patients with IgA nephropathy. Nephrol. Dial. Transplant. 27, 252-258 (2012).
39. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int. 77, 921-927 (2010).
40. Cattran, D. C. et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 76, 534-545 (2009).
41. Roberts, I. S. et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 76, 546-556 (2009).
42. Najafi, C. C. et al. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int. 59, 2156-2163 (2001).
43. Mittal, B., Hurwitz, S., Rennke, H. & Singh, A. K. New subcategories of class IV lupus nephritis: are there clinical, histologic, and outcome differences? Am. J. Kidney Dis. 44, 1050-1059 (2004).
44. Hill, G. S., Delahousse, M., Nochy, D. & Bariety, J. Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis. Kidney Int. 68, 2288-2297 (2005).
45. Yu, F. et al. Class IV-G and IV-S lupus nephritis in Chinese patients: a large cohort study from a single center. Lupus 18, 1073-1081 (2009).
46. Schwartz, M. M., Korbet, S. M. & Lewis, E. J. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol. Dial. Transplant. 23, 1298-1306 (2008).
47. Haring, C. M., Rietveld, A., van den Brand, J. A. & Berden, J. H. Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes. J. Am. Soc. Nephrol. 23, 149-154 (2012).
48. Churg, J. & Sobin, L. Renal Disease: Classification and Atlas of Glomerular Disease 1st edn (Igaku-Shoin, 1982).
49. Hill, G. S. et al. A new morphologic index for the evaluation of renal biopsies in lupus nephritis. Kidney Int. 58, 1160-1173 (2000).
50. Sumethkul, V., Chalermsanyakorn, P., Changsirikulchai, S. & Radinahamed, P. Lupus nephritis: a challenging cause of rapidly progressive crescentic glomerulonephritis. Lupus 9, 424-428 (2000).
51. Yu, F. et al. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int. 76, 307-317 (2009).
52. Horino, T. et al. Minimal change nephrotic syndrome associated with systemic lupus erythematosus. Nephrol. Dial. Transplant. 21, 230 (2006).
53. Hertig, A. et al. SLE and idiopathic nephrotic syndrome: coincidence or not? Am. J. Kidney Dis. 40, 1179-1184 (2002).
54. Desai, N., Cimbaluk, D., Lewis, E. J. & Whittier, W. L. Proteinuria in membranous lupus nephritis: the pathology is in the podocyte. Lupus 22, 461-468 (2013).
55. Kraft, S. W., Schwartz, M. M., Korbet, S. M. & Lewis, E. J. Glomerular podocytopathy in patients with systemic lupus erythematosus. J. Am. Soc. Nephrol. 16, 175-179 (2005).
56. Shea-Simonds, P., Cairns, T. D., Roufosse, C., Cook, T. & Vyse, T. J. Lupus podocytopathy. Rheumatology (Oxford) 48, 1616-1618 (2009).
57. Salvatore, S. P. et al. Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or lupuslike disease. Clin. J. Am. Soc. Nephrol. 7, 914-925 (2012).
58. Hu, W. et al. Clinical-morphological features and outcomes of lupus podocytopathy. Clin. J. Am. Soc. Nephrol. 11, 585-592 (2016).
59. Rezende, G. M. et al. Podocyte injury in pure membranous and proliferative lupus nephritis: distinct underlying mechanisms of proteinuria? Lupus 23, 255-262 (2014).
60. Wang, Y., Yu, F., Song, D., Wang, S. X. & Zhao, M. H. Podocyte involvement in lupus nephritis based on the 2003 ISN/RPS system: a large cohort study from a single centre. Rheumatology (Oxford) 53, 1235-1244 (2014).
61. Yu, F. et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int. 77, 820-829 (2010).
62. Hsieh, C. et al. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res. (Hoboken) 63, 865-874 (2011).
63. Alsuwaida, A. O. Interstitial inflammation and long-term renal outcomes in lupus nephritis. Lupus 22, 1446-1454 (2013).
64. Hill, G. S., Delahousse, M., Nochy, D., Mandet, C. & Bariety, J. Proteinuria and tubulointerstitial lesions in lupus nephritis. Kidney Int. 60, 1893-1903 (2001).
65. Hill, G. S. et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int. 59, 304-316 (2001).
66. Zappitelli, M., Duffy, C. M., Bernard, C. & Gupta, I. R. Evaluation of activity, chronicity and tubulointerstitial indices for childhood lupus nephritis. Pediatr. Nephrol. 23, 83-91 (2008).
67. Zhang, X. et al. A composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies. Kidney Int. 81, 401-406 (2012).
68. Appel, G. B., Pirani, C. L. & D'Agati, V. Renal vascular complications of systemic lupus erythematosus. J. Am. Soc. Nephrol. 4, 1499-1515 (1994).
69. Wu, L. H. et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int. 83, 715-723 (2013).
70. Barber, C. et al. Evaluation of clinical outcomes and renal vascular pathology among patients with lupus. Clin. J. Am. Soc. Nephrol. 7, 757-764 (2012).
71. Song, D. et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res. Ther. 15, R12 (2013).
72. Yu, F., Tan, Y. & Zhao, M. H. Lupus nephritis combined with renal injury due to thrombotic thrombocytopaenic purpura-haemolytic uraemic syndrome. Nephrol. Dial. Transplant. 25, 145-152 (2010).
73. Chu, H., Wu, L. H., Song, D., Yu, F. & Zhao, M. H. Noninflammatory necrotizing vasculopathy in lupus nephritis: a single-center experience. Lupus 23, 20-30 (2014).
74. Tan, Y., Yu, F. & Liu, G. Diverse vascular lesions in systemic lupus erythematosus and clinical implications. Curr. Opin. Nephrol. Hypertens. 23, 218-223 (2014).
75. Huang, J. et al. Renal interstitial arteriosclerotic lesions in lupus nephritis patients: a cohort study from China. PLoS ONE 10, e0141547 (2015).
76. Liu, Z. et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann. Intern. Med. 162, 18-26 (2015).
77. Allison, S. J. Lupus nephritis: multitarget induction therapy for LN. Nat. Rev. Nephrol. 11, 3 (2015).
78. Anders, H. J. & Fogo, A. B. Immunopathology of lupus nephritis. Semin. Immunopathol. 36, 443-459 (2014).
79. Bruschi, M. et al. Glomerular autoimmune multicomponents of human lupus nephritis in vivo: alpha-enolase and annexin AI. J. Am. Soc. Nephrol. 25, 2483-2498 (2014).
80. Chan, T. M. Treatment of severe lupus nephritis: the new horizon. Nat. Rev. Nephrol. 11, 46-61 (2015).
81. Lech, M. & Anders, H. J. The pathogenesis of lupus nephritis. J. Am. Soc. Nephrol. 24, 1357-1366 (2013).
82. Lorenz, G., Desai, J. & Anders, H. J. Lupus nephritis: update on mechanisms of systemic autoimmunity and kidney immunopathology. Curr. Opin. Nephrol. Hypertens. 23, 211-217 (2014).
83. Mohan, C. & Putterman, C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat. Rev. Nephrol. 11, 329-341 (2015).
84. Nowling, T. K. & Gilkeson, G. S. Mechanisms of tissue injury in lupus nephritis. Arthritis Res. Ther. 13, 250 (2011).
85. Bekar, K. W. et al. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum. 62, 2443-2457 (2010).
86. Ramanujam, M. et al. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum. 62, 1457-1468 (2010).
87. Chan, T. M. et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med. 343, 1156-1162 (2000).
88. Ginzler, E. M. et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353, 2219-2228 (2005).
89. Hannah, J., Casian, A. & D'Cruz, D. Tacrolimus use in lupus nephritis: a systematic review and meta-analysis. Autoimmun. Rev. 15, 93-101 (2016).
90. Chen, W. et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am. J. Kidney Dis. 57, 235-244 (2011).
91. Li, X. et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol. Dial. Transplant. 27, 1467-1472 (2012).
92. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02141672 (2017).
93. Corapi, K. M., Dooley, M. A., Pendergraft, W. F. III. Comparison and evaluation of lupus nephritis response criteria in lupus activity indices andclinical trials. Arthritis Res. Ther. 17, 110 (2015).
94. Mok, C. C. Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma. Nat. Rev. Nephrol. 5, 212-220 (2009).
95. Yap, D. Y. et al. Long-term data on tacrolimus treatment in lupus nephritis. Rheumatology (Oxford) 53, 2232-2237 (2014).
96. Beck, L. H. Jr & Salant, D. J. Treatment of membranous lupus nephritis: where are we now? J. Am. Soc. Nephrol. 20, 690-691 (2009).
97. Austin, H. A. III, Illei, G. G., Braun, M. J. & Balow, J. E. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J. Am. Soc. Nephrol. 20, 901-911 (2009).
98. Migliorini, A. et al. The antiviral cytokines IFN-alpha and IFN-beta modulate parietal epithelial cells and promote podocyte loss: implications for IFN toxicity, viral glomerulonephritis, and glomerular regeneration. Am. J. Pathol. 183, 431-440 (2013).
99. Mesnard, L. et al. Invariant natural killer T cells and TGF-beta attenuate anti-GBM glomerulonephritis. J. Am. Soc. Nephrol. 20, 1282-1292 (2009).
100. Paust, H. J. et al. The IL-23/Th17 axis contributes to renal injury in experimental glomerulonephritis. J. Am. Soc. Nephrol. 20, 969-979 (2009).
101. Smeets, B. et al. Tracing the origin of glomerular extracapillary lesions from parietal epithelial cells. J. Am. Soc. Nephrol. 20, 2604-2615 (2009).
102. Ohse, T. et al. De novo expression of podocyte proteins in parietal epithelial cells during experimental glomerular disease. Am. J. Physiol. Renal Physiol. 298, F702-F711 (2010).
103. Nasr, S. H. et al. Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. Clin. J. Am. Soc. Nephrol. 3, 682-690 (2008).
104. Lee, S. S. et al. Antilactoferrin antibody in systemic lupus erythematosus. Br. J. Rheumatol. 31, 669-673 (1992).
105. Chin, H. J. et al. Clinical implications of antineutrophil cytoplasmic antibody test in lupus nephritis. Am. J. Nephrol. 20, 57-63 (2000).
106. Zhao, M. H., Liu, N., Zhang, Y. K. & Wang, H. Y. Antineutrophil cytoplasmic autoantibodies (ANCA) and their target antigens in Chinese patients with lupus nephritis. Nephrol. Dial. Transplant. 13, 2821-2824 (1998).
107. Xiao, H. et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J. Am. Soc. Nephrol. 25, 225-231 (2014).
108. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01363388 (2016).
109. Perysinaki, G. S. et al. Podocyte main slit diaphragm proteins, nephrin and podocin, are affected at early stages of lupus nephritis and correlate with disease histology. Lupus 20, 781-791 (2011).
110. Chang, A. et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J. Immunol. 186, 1849-1860 (2011).
111. Kinloch, A. J. et al. Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis. Arthritis Rheumatol. 66, 3359-3370 (2014).
112. Yung, S. et al. Anti-dsDNA antibody induces soluble fibronectin secretion by proximal renal tubular epithelial cells and downstream increase of TGF-beta1 and collagen synthesis. J. Autoimmun. 58, 111-122 (2015).
113. Yung, S. & Chan, T. M. Molecular and immunological basis of tubulo-interstitial injury in lupus nephritis: a comprehensive review. Clin. Rev. Allergy Immunol. 52, 149-163 (2016).
114. Ko, K. et al. BCL-2 as a therapeutic target in human tubulointerstitial inflammation. Arthritis Rheumatol. 68, 2740-2751 (2016).
115. Frieri, M. Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. Curr. Allergy Asthma Rep. 12, 25-32 (2012).
116. Chua, J. S. et al. Complement factor C4d is a common denominator in thrombotic microangiopathy. J. Am. Soc. Nephrol. 26, 2239-2247 (2015).
117. Cohen, D. et al. Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis. Arthritis Rheum. 58, 2460-2469 (2008).
118. El-Husseini, A. et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am. J. Kidney Dis. 65, 127-130 (2015).
119. Coppo, R. et al. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr. Nephrol. 30, 167-172 (2015).
120. Tonooka, K., Ito, H., Shibata, T. & Ozaki, S. Recombinant human soluble thrombomodulin for treatment of thrombotic microangiopathy associated with lupus nephritis. J. Rheumatol. 39, 1766-1767 (2012).
121. Leffler, J., Bengtsson, A. A. & Blom, A. M. The complement system in systemic lupus erythematosus: an update. Ann. Rheum. Dis. 73, 1601-1606 (2014).
122. Merrill, J. T. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222-233 (2010).
123. Mysler, E. F. et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 65, 2368-2379 (2013).
124. Reddy, V., Jayne, D., Close, D. & Isenberg, D. B-Cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res. Ther. 15 (Suppl. 1), S2 (2013).
125. Roccatello, D. et al. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-clinical response compared to literature and immunological re-assessment. Autoimmun. Rev. 14, 1123-1130 (2015).
126. US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT01773616?term=NCT01773616&rank=1 (2017).
127. Condon, M. B. et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann. Rheum. Dis. 72, 1280-1286 (2013).
128. US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02550652?term=NCT02550652&rank=1 (2017).
129. Karageorgas, T. et al. Successful treatment of life-threatening autoimmune haemolytic anaemia with ofatumumab in a patient with systemic lupus erythematosus. Rheumatology (Oxford) 55, 2085-2087 (2016).
130. Reddy, V., Dahal, L. N., Cragg, M. S. & Leandro, M. Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer? Drug Discov. Today 21, 1330-1338 (2016).
131. Dooley, M. A. et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 22, 63-72 (2013).
132. Sciascia, S. et al. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review. Autoimmun. Rev. 16, 287-293 (2017).
133. Ichikawa, H. T. et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum. 64, 493-503 (2012).
134. Neubert, K. et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 14, 748-755 (2008).
135. Khodadadi, L. et al. Bortezomib plus continuous B cell depletion results in sustained plasma cell depletion and amelioration of lupus nephritis in NZB/W F1 mice. PLoS ONE 10, e0135081 (2015).
136. Furie, R. et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 66, 379-389 (2014).
137. Fragoso-Loyo, H. E. & Dooley, M. A. Efficacy of the euro-lupus nephritis regimen combined with abatacept versus placebo in a North American lupus nephritis population. Ann. Rheum. Dis. 73 (Suppl. 2), 77-78 (2014).
138. Group, A. T. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol. 66, 3096-3104 (2014).
139. US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT01714817?term=NCT01714817&rank=1 (2017).
140. Rovin, B. H. & Parikh, S. V. Lupus nephritis: the evolving role of novel therapeutics. Am. J. Kidney Dis. 63, 677-690 (2014).
141. Gu, F. et al. Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy. Clin. Rheumatol. 33, 1611-1619 (2014).
142. Olson, S. W. et al. Elevated subclinical double-stranded DNA antibodies and future proliferative lupus nephritis. Clin. J. Am. Soc. Nephrol. 8, 1702-1708 (2013).
143. Orbai, A. M. et al. Anti-C1q antibodies in systemic lupus erythematosus. Lupus 24, 42-49 (2015).
144. Pfueller, B., Wolbart, K., Bruns, A., Burmester, G. R. & Hiepe, F. Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: a pilot study. Arthritis Rheum. 44, 1962-1963 (2001).
145. Suzuki, K. The role of immunoadsorption using dextran-sulfate cellulose columns in the treatment of systemic lupus erythematosus. Ther. Apher. 4, 239-243 (2000).